Sotatercept significantly reduces pulmonary vascular resistance in patients with CpcPH–HFpEF compared with placebo, according to a trial.
pill, medicine in palm of hand Researchers’ goal was to determine empagliflozin’s impact on the central hemodynamic parameters of patients with heart failure with reduced ejection fraction.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results